Researchers discover new way to 'rescue' treatment sensitivity of breast cancer cells

May 10, 2010

A study by researchers from the Georgetown Lombardi Comprehensive Cancer Center at Georgetown University Medical Center (GUMC) identifies a potential new combination therapy to "rescue" treatment sensitivity to fulvestrant in estrogen receptor positive breast cancers. The findings were published on May 15, 2010 as the cover story of Molecular Cancer Therapeutics.

Fulvestrant is a common second-line therapy for women whose cancer progresses following anti-estrogen therapy. In this paper, Lombardi researchers identify a cytokine, a small called IFNγ, which appears to increase or even rescue sensitivity to fulvestrant.

Led by Robert Clarke, PhD, DSc, professor of oncology and physiology & biophysics at Lombardi, the research team identified a key downstream regulator of sensitivity to fulvestrant - the protein IRF1. When cells were treated with both fulvestrant and IFNγ, Clarke and colleagues saw an increase in expression of IRF1, which resulted in increased apoptosis - or programmed cell death - of the cancer cells.

The American Cancer Society estimates that in 2009, 192,000 women were diagnosed with invasive breast cancer, and approximately 70 percent of these cases were considered to be estrogen receptor-positive (ER+), meaning that estrogen and its receptor drive the disease. While a number of anti-estrogen therapies are able to successfully treat these cancers, resistance may develop, often leading to disease progression.

"This finding is significant because we and others in the field have been searching for a long time for clinically relevant ways to make anti-estrogen therapies more effective for women with ER+ ," says Rebecca Riggins, PhD, assistant professor of oncology at Lombardi and co-author of the paper.

Most of the genes and proteins regulated by the are unknown, and the molecular effects of therapies such as anti-hormonal drugs are also largely unidentified, says Clarke, who also serves as interim director of GUMC's Biomedical Graduate Research Organization.

However, in this paper, the research team has identified that the induction of IRF1 expression involves regulation of well-known cell fate proteins including NF- κB and the BCL-2 family of proteins, leading to apoptotic pathways. Ultimately, Clarke and colleagues suggest that a combination of anti-estrogens and compounds that up-regulate IRF1 expression - like IFNγ - may be useful for the treatment of anti-estrogen resistant ER+ breast cancers.

Clarke was also recently awarded a major program grant by the National Cancer Institute to lead a Center for Cancer Systems Biology addressing estrogen receptor signaling in breast resistance.

Explore further: Americans' risk of dying from cancer is falling, CDC finds

Related Stories

Recommended for you

Spicy treatment the answer to aggressive cancer?

2 hours ago

It has been treasured by food lovers for thousands of years for its rich golden colour, peppery flavour and mustardy aroma…and now turmeric may also have a role in fighting cancer.

Cancer survivors who smoke perceive less risk from tobacco

19 hours ago

Cancer survivors who smoke report fewer negative opinions about smoking, have more barriers to quitting, and are around other smokers more often than survivors who had quit before or after their diagnosis, according to a ...

Melanoma mutation rewires cell metabolism

19 hours ago

A mutation found in most melanomas rewires cancer cells' metabolism, making them dependent on a ketogenesis enzyme, researchers at Winship Cancer Institute of Emory University have discovered.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.